HomeToday’s HighlightsAmgen and UCB granted FDA approval of Evenity for osteoporosis in menopausal women at risk of bone fracture Amgen and UCB granted FDA approval of Evenity for osteoporosis in menopausal women at risk of bone fracture Today’s Highlights April 10, 2019 Amgen and UDB Granted FDA Approval of Evenity™ Amgen (AMGN) and UCB Pharmaceuticals (This content is for paid subscribers. Please click here to subscribe or here to log in. Today’s Highlights Amgen (AMGN), UCB Pharmaceuticals (UCB) April 10, 2019 Tweet Pin It Other Articles Eli Lilly’s Oral GLP-1, Orforglipron, is Superior to Oral Semaglutide in Head-to-Head Trial September 17, 2025 0 Alkermes: Detailed Positive Results from Vibrance-1 Phase 2 Study of Alixorexton in Patients with Narcolepsy Type 1 at World Sleep Congress 2025 September 8, 2025 0 Ionis Pharmaceuticals Product Olezarsen Significantly Reduces Triglycerides and Acute Pancreatitis Events in Landmark Pivotal Studies for People with Severe Hypertriglyceridemia September 2, 2025 0 BioArctic and Novartis Sign a Collaboration and License Agreement Using BrainTransporter™ August 27, 2025 0